Elevated Serum Neuropeptide FF Levels Are Associated with Cognitive Decline in Patients with Spinal Cord Injury

Background. Spinal cord injury (SCI) has high incidence globally and is frequently accompanied by subsequent cognitive decline. Accurate early risk-categorization of SCI patients for cognitive decline using biomarkers can enable the timely application of appropriate neuroprotective measures and the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shifei Sun, Shilong Sun, Yan Meng, Bin Shi, Yuanzhen Chen
Formato:	article
Lenguaje:	EN
Publicado:	Hindawi Limited 2021
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/f2fb25d0984a45d2bae1f167564bd94a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f2fb25d0984a45d2bae1f167564bd94a
record_format	dspace
spelling	oai:doaj.org-article:f2fb25d0984a45d2bae1f167564bd94a2021-11-22T01:10:59ZElevated Serum Neuropeptide FF Levels Are Associated with Cognitive Decline in Patients with Spinal Cord Injury1875-863010.1155/2021/4549049https://doaj.org/article/f2fb25d0984a45d2bae1f167564bd94a2021-01-01T00:00:00Zhttp://dx.doi.org/10.1155/2021/4549049https://doaj.org/toc/1875-8630Background. Spinal cord injury (SCI) has high incidence globally and is frequently accompanied by subsequent cognitive decline. Accurate early risk-categorization of SCI patients for cognitive decline using biomarkers can enable the timely application of appropriate neuroprotective measures and the development of new agents for the management of SCI-associated cognitive decline. Neuropeptide FF is an endogenous neuropeptide with a multitude of functions and is associated with neuroinflammatory processes. This prospective study investigated the predictive value of serum neuropeptide FF levels measured after acute SCI for subsequent cognitive decline. Methods. 88 patients presenting with acute SCI without preexisting neurological injury, brain trauma, or severe systemic illness and 60 healthy controls were recruited. Serum neuropeptide FF levels, clinical, and routine laboratory variables including low-density lipoprotein, high-density lipoprotein, fasting blood glucose, total triiodothyronine (TT3), total thyroxine (TT4), and thyroid-stimulating hormone (TSH) levels collected from all subjects were assessed. Montreal cognitive assessment (MoCA) was performed 3 months after enrollment. SCI patients were grouped according to quartile of serum neuropeptide FF level and MoCA scores were compared using ANOVA. Additionally, multivariate linear regression with clinical and laboratory variables was performed to predict MoCA scores. Results. SCI patients displayed significantly higher baseline serum neuropeptide FF levels than healthy controls (38.5±4.1 versus 23.4±2.0 pg/ml, p<0.001∗∗). SCI patients in higher quartiles of baseline serum neuropeptide FF displayed significantly lower MoCA scores at 3 months. Linear regression analysis indicated serum neuropeptide FF levels as a significant independent predictor of worse MoCA scores after SCI (r=0.331, p=0.034∗). Conclusion. Early serum neuropeptide FF levels significantly and independently predicted cognitive decline after acute SCI among patients without preexisting neurological disorders.Shifei SunShilong SunYan MengBin ShiYuanzhen ChenHindawi LimitedarticleMedicine (General)R5-920ENDisease Markers, Vol 2021 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Shifei Sun Shilong Sun Yan Meng Bin Shi Yuanzhen Chen Elevated Serum Neuropeptide FF Levels Are Associated with Cognitive Decline in Patients with Spinal Cord Injury
description	Background. Spinal cord injury (SCI) has high incidence globally and is frequently accompanied by subsequent cognitive decline. Accurate early risk-categorization of SCI patients for cognitive decline using biomarkers can enable the timely application of appropriate neuroprotective measures and the development of new agents for the management of SCI-associated cognitive decline. Neuropeptide FF is an endogenous neuropeptide with a multitude of functions and is associated with neuroinflammatory processes. This prospective study investigated the predictive value of serum neuropeptide FF levels measured after acute SCI for subsequent cognitive decline. Methods. 88 patients presenting with acute SCI without preexisting neurological injury, brain trauma, or severe systemic illness and 60 healthy controls were recruited. Serum neuropeptide FF levels, clinical, and routine laboratory variables including low-density lipoprotein, high-density lipoprotein, fasting blood glucose, total triiodothyronine (TT3), total thyroxine (TT4), and thyroid-stimulating hormone (TSH) levels collected from all subjects were assessed. Montreal cognitive assessment (MoCA) was performed 3 months after enrollment. SCI patients were grouped according to quartile of serum neuropeptide FF level and MoCA scores were compared using ANOVA. Additionally, multivariate linear regression with clinical and laboratory variables was performed to predict MoCA scores. Results. SCI patients displayed significantly higher baseline serum neuropeptide FF levels than healthy controls (38.5±4.1 versus 23.4±2.0 pg/ml, p<0.001∗∗). SCI patients in higher quartiles of baseline serum neuropeptide FF displayed significantly lower MoCA scores at 3 months. Linear regression analysis indicated serum neuropeptide FF levels as a significant independent predictor of worse MoCA scores after SCI (r=0.331, p=0.034∗). Conclusion. Early serum neuropeptide FF levels significantly and independently predicted cognitive decline after acute SCI among patients without preexisting neurological disorders.
format	article
author	Shifei Sun Shilong Sun Yan Meng Bin Shi Yuanzhen Chen
author_facet	Shifei Sun Shilong Sun Yan Meng Bin Shi Yuanzhen Chen
author_sort	Shifei Sun
title	Elevated Serum Neuropeptide FF Levels Are Associated with Cognitive Decline in Patients with Spinal Cord Injury
title_short	Elevated Serum Neuropeptide FF Levels Are Associated with Cognitive Decline in Patients with Spinal Cord Injury
title_full	Elevated Serum Neuropeptide FF Levels Are Associated with Cognitive Decline in Patients with Spinal Cord Injury
title_fullStr	Elevated Serum Neuropeptide FF Levels Are Associated with Cognitive Decline in Patients with Spinal Cord Injury
title_full_unstemmed	Elevated Serum Neuropeptide FF Levels Are Associated with Cognitive Decline in Patients with Spinal Cord Injury
title_sort	elevated serum neuropeptide ff levels are associated with cognitive decline in patients with spinal cord injury
publisher	Hindawi Limited
publishDate	2021
url	https://doaj.org/article/f2fb25d0984a45d2bae1f167564bd94a
work_keys_str_mv	AT shifeisun elevatedserumneuropeptidefflevelsareassociatedwithcognitivedeclineinpatientswithspinalcordinjury AT shilongsun elevatedserumneuropeptidefflevelsareassociatedwithcognitivedeclineinpatientswithspinalcordinjury AT yanmeng elevatedserumneuropeptidefflevelsareassociatedwithcognitivedeclineinpatientswithspinalcordinjury AT binshi elevatedserumneuropeptidefflevelsareassociatedwithcognitivedeclineinpatientswithspinalcordinjury AT yuanzhenchen elevatedserumneuropeptidefflevelsareassociatedwithcognitivedeclineinpatientswithspinalcordinjury
_version_	1718418377351888896

Elevated Serum Neuropeptide FF Levels Are Associated with Cognitive Decline in Patients with Spinal Cord Injury

Ejemplares similares